The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment

Abstract Sorafenib is currently the first‐line therapy for advanced hepatocellular carcinoma (aHCC) patients. However, the outcomes and prognostic factors of sorafenib therapy have not been well investigated. We aimed to investigate the pretreatment factors and outcomes among Taiwanese aHCC patients...

Full description

Bibliographic Details
Main Authors: Ming‐Lun Yeh, Chung‐Feng Huang, Ching‐I Huang, Ming‐Yen Hsieh, Nei‐Jen Hou, I‐Hung Lin, Po‐Cheng Liang, Yi‐Shan Tsai, Meng‐Hsuan Hsieh, Zu‐Yau Lin, Shinn‐Chern Chen, Chia‐Yen Dai, Jee‐Fu Huang, Ming‐Lung Yu, Wan‐Long Chuang
Format: Article
Language:English
Published: Wiley 2019-10-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
advance
hepatocellular carcinoma
sorafenib
survival
Online Access:https://doi.org/10.1002/kjm2.12105

Internet

https://doi.org/10.1002/kjm2.12105

Similar Items